- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.07. | Curanex Pharmaceuticals Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.06. | T-CURX Acquires Pantherna Therapeutics to Boost Clinical Validation of In-Vivo CAR-T Therapies | 1 | Contract Pharma | ||
| 01.06. | LNP-Delivery im Fokus: T-CURX übernimmt Pantherna | 1 | transkript.de | ||
| 14.05. | Curanex Pharmaceuticals Inc: Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | 210 | GlobeNewswire (Europe) | Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated... ► Artikel lesen | |
| 14.05. | Curanex Pharmaceuticals Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| CURANEX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.05. | Curanex Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline | 259 | GlobeNewswire (Europe) | Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically... ► Artikel lesen | |
| 08.04. | EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives | 1 | Benzinga.com | ||
| 06.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care | 1 | GlobeNewswire (USA) | ||
| 06.04. | EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy | 1 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc: Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development ... | 363 | GlobeNewswire (Europe) | Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex"... ► Artikel lesen | |
| 02.04. | EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases | 2 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 30.03. | Curanex Pharmaceuticals Inc: Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission | 428 | GlobeNewswire (Europe) | Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex... ► Artikel lesen | |
| 30.03. | Curanex Pharmaceuticals Inc - 10-K, Annual Report | - | SEC Filings | ||
| 18.03. | Curanex Pharmaceuticals Inc: Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission | 242 | GlobeNewswire (Europe) | Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March... ► Artikel lesen | |
| 12.03. | Curanex stärkt wissenschaftlichen Beirat vor wichtigem Zulassungsantrag | - | Investing.com Deutsch | ||
| 12.03. | Curanex adds two advisors to scientific board ahead of IND filing | 1 | Investing.com | ||
| 12.03. | Curanex Pharmaceuticals Inc: Curanex Expands Scientific Advisory Board With Two Distinguished Researchers | 1 | GlobeNewswire (USA) | ||
| 11.03. | Curanex adds two pharmaceutical veterans to advisory board | 2 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANOPY GROWTH | 0,819 | -1,18 % | Drama um Canopy, Tilray & Co?: Anhörungsprozess zu Cannabis endet - Stürzt die DEA den Sektor ins Chaos? | © Foto: adobe.stock.comAm 29. Juni begann der Anhörungsprozess der DEA zur möglichen Neueinstufung von Freizeit-Cannabis in Schedule III. Mittlerweile steht der Anhörungsprozess vor seinem Ende. Was... ► Artikel lesen | |
| EYEPOINT | 10,100 | -6,48 % | EyePoint, Inc.: EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) | - COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients --... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,850 | -3,85 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| COMPASS PATHWAYS | 10,200 | +4,62 % | Compass Pathfinder Limited: Compass Pathways gibt am 5. August 2026 die Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2026 bekannt | Die Geschäftsführung von Compass wird um 8:00 Uhr ET (13:00 Uhr britischer Zeit) eine Telefonkonferenz abhalten
Compass Pathways plc (Nasdaq: CMPS), ein Biotechnologieunternehmen, das sich der... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,045 | +3,74 % | Corbus gets green light to begin pivotal trial of ADC for oropharyngeal cancer | ||
| DARE BIOSCIENCE | 1,355 | +5,86 % | Daré Bioscience geht Partnerschaft mit Telemedizin-Plattform für Menopause ein | ||
| CITIUS PHARMACEUTICALS | 0,627 | +5,22 % | Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | $5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®
Citius Pharma raised $5 million in a registered direct offering; Citius... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 2,900 | +1,40 % | Natera, Eledon Partner On Kidney Transplant Monitoring Test For Phase 3 Trial; Stock Up | WASHINGTON (dpa-AFX) - Cell-free DNA testing company Natera, Inc. (NTRA) and Eledon Pharmaceuticals, Inc. (ELDN) announced on Thursday that they have entered into a partnership to use Natera's... ► Artikel lesen | |
| CENTESSA PHARMACEUTICALS | 34,600 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.06.2026ISIN NameCA04058Q1054 ARIZONA... ► Artikel lesen | |
| EXICURE | 1,130 | -0,88 % | Exicure, Inc.: Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance | WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics... ► Artikel lesen | |
| CHINA SXT PHARMACEUTICALS | 0,069 | -10,40 % | Morning Market Movers: InMed Pharmaceuticals, INLIF Limited, China SXT Pharmaceuticals, Advanced Biomed See Big Swings | BEIJING (dpa-AFX) - At 8:30 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COSMOS HEALTH | 0,188 | -7,33 % | Cosmos Health Inc.: Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels | Digital subscription platform brings together the Company's proprietary consumer health products across consumer (B2C) and corporate (B2B) channelsCustomers can begin through one of three paths: a free... ► Artikel lesen | |
| CHAMPIONS ONCOLOGY | 4,940 | +7,86 % | Champions Oncology outlines fiscal 2027 plan with Corellia fully funded as it reports $59.4M revenue and $1.6M adjusted EBITDA | ||
| CUMBERLAND PHARMACEUTICALS | 7,560 | +5,29 % | Dividendenbekanntmachungen (03.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR BF SPA IT0005187460 - 0,038 EUR CITIZENS & NORTHERN CORPORATION US1729221069 0... ► Artikel lesen | |
| CDT EQUITY | 3,040 | +6,11 % | CDT Equity Inc. - 8-K, Current Report |
CURANEX PHARMACEUTICALS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,204 Euro und damit -4,32 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURANEX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.